Friday 15 July

Saturday 16 July

 
 

 

Growing up with HIV

Invited lecture: Growing up with HIV in resource-rich countries

R. Hazra

Pres.

Invited lecture: The challenge of growing up with HIV in resource limited countries

P. Musoke

Pres.

 

Sexual Risk Behavior among Perinatally HIV-Infected Youth in the US: Predictors and Implications for Intervention Development

K. Tassiopoulos

Pres.

 

Body composition and metabolic abnormalities of perinatally HIV-infected children in South Africa on long-term ARV treatment

S. Shiau

Pres.

 

Project Control: Evaluation of a brief HIV counseling video to improve teenagers’ risk reduction behavior

Y. Calderon

Pres.

 

High drug resistance prevalence among vertically hiv-infected patients transferred from paediatric care to adult units in spain

M. de Mulder

Pres.

 

Routine HIV testing in adolescents and young adults presenting to an outpatient site in Durban, South Africa

L. Ramirez

Pres.

Screening of Adolescents and Young Adults for HIV in a Large Urban Pediatric Emergency Department: How to Do it Right?

N. Rakhmanina

Pres.

 

 

Poster Presentation Session 1

Population pharmacokinetics of etravirine in HIV-1-infected treatment-experienced children and adolescents (6 to <18 years)

T. Kakuda

Pres.

 

24-week efficacy, safety, tolerability and pharmacokinetics of darunavir/ritonavir qd in treatment-naive adolescents aged 12 to <18 years in DIONE

P. Flynn

Pres.

 

Efavirenz plasma concentrations during 24 months follow-up post-ART in HIV-infected South African children

M. Viljoen

Pres.

 

Maraviroc (MVC) pharmacokinetics (PK) in CCR5-tropic HIV-1-infected children aged 2-<18 years: preliminary results from Study A4001031

L. McFadyen

Pres.

 

Second-line highly active antiretroviral therapy in Asian HIV-infected children

T. Bunupuradah

Pres.

 

Patterns of first-line antiretroviral regimen and switch to second-line in West African children on ART. The IeDEA paediatric West African Database.

V. Lerloy

Pres.

 

 

Controversies in Pediatric Treatment

Debate: "Viral load monitoring should be routine for children in resource-limited countries"

Invited lecture: Pro - standpoint

L. Kuhn

Pres.

 

Invited lecture: Con - standpoint

D. Gibb

Pres.

 

Round table Discussion: Optimal first-line regimen choice in children - NNRTI or PI?

First Line Therapy Considerations for Young Children in Light of P1060

P. Palumbo

not available

What have we learned from the PENPACT1 trial?

G. Tudor-Williams

Pres.

 

Should PI-based Therapy Be Continued Indefinitely?

A. Coovadia

Pres.

 

 

Predictive value of six-week viral load on mortality in HIV-infected Zimbabwean infants

A. Prendergast

Pres.

 

Treatment efficacy in European children starting cART in infancy: factors associated with viro-immunological response and 1st-line therapy duration

M. Penazzato

Pres.

Predicting 1-year mortality using current CD4 percent and count in order to guide switching therapy in children on ART in Southern Africa

M-A. Davies

Pres.

 

Long-term consequences of planned treatment interruptions in HIV-infected children: results from the PENTA 11/TICCH trial

A. Compagnucci

Pres.

 

 

Clinical Case presentations: Difficult cases in management of HIV in Children

Management of treatment failure, including issues of long-term ARV toxicity

H. Rabie

Pres.

Opportunistic infection

T. Puthanakit

Pres.

 

Adolescent issues

R. Ferrand

Pres.

 

 

 

Virology Education -
a Medical Education company